ResMed (RMD) Valuation Check As Investors Await Fiscal Q2 Earnings Update

ResMed (RMD) is back in focus as the company approaches its fiscal second quarter 2026 earnings release, with analysts watching closely after several quarters of topping Wall Street earnings expectations. See our latest analysis for ResMed. At a latest share price of $244.81, ResMed’s 90 day share price return of a 13.58% decline contrasts with a 1 year total shareholder return of 5.06% and a 3 year total shareholder return of 20.05%. This suggests recent momentum has faded even as longer term holders remain in positive territory, which can influence how investors think about the upcoming earnings and the risk profile around the stock. If ResMed’s earnings update has you reassessing healthcare exposure, it could be a good moment to scan other opportunities across healthcare stocks. With ResMed trading at $244.81 and sitting at a small intrinsic discount alongside an analyst price target of $291.80, you have to ask yourself: is there still upside here, or is the market already pricing in future growth? Most Popular Narrative: 17.1% Undervalued Compared with ResMed’s last close at $244.81, the most followed narrative points to a higher fair value, anchored in earnings power and margins over the next few years. Optimization initiatives in procurement, manufacturing, and logistics along with the build-out of the U.S. manufacturing footprint are structurally improving gross margins, which, when combined with operating leverage from global scale, are expected to boost overall earnings and free cash flow. Read the complete narrative. Curious what is behind that confidence in higher earnings and cash flow? The narrative leans on measured revenue expansion, thicker margins, and a premium yet moderated future earnings multiple. The full set of assumptions shows how those pieces combine into a higher fair value than today’s share price. Result: Fair Value of $295.13 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, that upside narrative can be challenged if GLP-1 uptake weighs on device demand or if regulatory and compliance costs rise faster than expected. Find out about the key risks to this ResMed narrative. Build Your Own ResMed Narrative If you see the numbers differently or simply prefer to test your own assumptions against the data, you can build a personalized view in minutes: Do it your way. A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding ResMed. Ready To Hunt For Your Next Idea? If ResMed has sharpened your thinking, do not stop there. Use the Screener to quickly surface fresh stock ideas that fit exactly what you care about. Target reliable income by focusing on these 14 dividend stocks with yields > 3% that already offer yields above 3% and may suit a steadier, cash flow focused approach. Tap into new trends by scanning these 25 AI penny stocks that are tied to real businesses applying artificial intelligence in practical, revenue generating ways. Zero in on potential mispricings with these 878 undervalued stocks based on cash flows that our models flag as trading below their estimated cash flow based value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.